Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

Fintel reports that on July 30, 2025, Barclays upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Norfolk Southern ( NSC) was down 2% in premarket trade after Union Pacific Corporation (UNP) and the company announced an ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...